Rheumatoid arthritis treatment and monitoring of outcomes - Where we are in 2007? Controversies and opportunities

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 4, 2007, Pages 300-305

  Yazici, Yusuf ^a,b,d   Abramson, Steven B ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; ATACICEPT; ATLIZUMAB; BELIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; OFATUMUMAB; PLACEBO; RITUXIMAB; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; B CELL LYMPHOMA; BENIGN TUMOR; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFECTION; JOINT SWELLING; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NEUTROPHIL COUNT; PATIENT ASSESSMENT; PATIENT CARE; PATIENT MONITORING; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEALTH STATUS; HUMANS; METHOTREXATE; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 37449015503     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Emery P. Treatment of rheumatoid arthritis. BMJ. 2006;332:152-5.
2. Pincus T, Yazici Y, Sokka T, Aletaha D, et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(Suppl 31):179-85.
3. Yazici Y, Sokka T, Kautiainen H, et al. Long-term safety of methotrexate in routine clinical care: Discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis. 2005; 64:207-11.
4. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet. 2004;364(9430):263-9.
5. Yazici Y, Yazici H. TNF Inhibitors (TNFi): Useful additional therapy to methotrexate (MTX) in rheumatoid arthritis patients with severe disease. Arthritis Rheum. 2006;54:S246.
6. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
7. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-TNF agents in rheumatoid arthritis. Arthritis and Rheum. 2003;48:313-8.
8. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria of most recent clinical trials. J Rheumatol. 2003;30:1138-46.
9. Gogus F, Yazici Y, Yazici H. Eligibility for inclusion criteria in use for rheumatoid arthritis clinical trials in a Turkish cohort. Arthritis and Rheum. 2003;48(9 Suppl):S128.
10. Yazici Y, Kulman I. Majority of rheumatoid arthritis patients in routine care do not meet inclusion criteria for RA clinical trials. Ann Rheum Dis. 2004;63(Suppl 1):183.
11. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med. 2006;144:865-76.
12. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005; 353:1114-23.
13. Boers M. Abatacept in rheumatoid arthritis: A new branch on the "biologics" tree. Ann Intern Med. 2006;144:933-5.
14. Emery P, Fleischmann R, Filipowicz-Sosmowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 2006; 54:1390-400.
15. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806.
16. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232-4.
17. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995;34:321-5.
18. Legendre F, Dudhia J, Pujol JP, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes: Association with a down-regulation of SOX9 expression. J Biol Chem. 2003;278:2903-12.
19. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54:2817-29.
20. Østergaard M, Wiell C, Dawes PT, et al. First clinical results of HuMax CD20 fully human monoclonal IgG1 antibody treatment in rheumatoid arthritis. Ann Rheum Dis 2006;65:(SII):58.
21. Genovese M, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness to belimumab (BmAb) in combination with standard of care therapy in RF+, TNFa-Inhibitor and methotrexate partial responder subgroups of subjects with moderate-severe rheumatoid arthritis. Arthritis Rheum. 2005;52;(Suppl).
22. Munafo A, Rossier C, Peter N, et al. TACI-IG in patients with rheumatoid arthritis: An exploratory, multi-centre, double blind, placebo-controlled, dose escalating, single and repeat dose phase IB study. Ann Rheum Dis. 2006;65(SII):108.
23. Baker M, Stringer F, Stephens P. Pharmacokinetic properties of the anti-TNF agent certolizumab pegol. Ann Rheum Dis. 2006;65:(SII)175.
24. Kay J, Matteson EL, Dasgupta B, Nash P, et al. DAS28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial. Ann Rheum Dis. 2006;65(SII):323.
25. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52:3381-90.
26. Pincus T, Segurado OG. Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis. 2006;65:820-2.
27. Pincus T, Sokka T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol. 2003;17:753-81.
28. Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient care: Is it better to have 80% of the information in 100% of patients or 100% of the information in 5% of patients? J Rheumatol. 2005;32:575-7.
29. Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 1998;41:1564-70.
30. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(Suppl 39):S100-8.
31. Cush J. Global arthritis score: A rapid practice tool for rheumatoid. Arthritis (RA) assessment. Arthritis Rheum. 2005;52(Suppl):S686.
32. Pincus T, Yazici Y, Bergman M, et al. A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: A patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvement." Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S060-73.
33. Pincus T, Chung C, Segurado OG, et al. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2146-52. Epub 2006 Oct 15.
34. Pincus T, Yazici Y, Bergman M, et al. Simplified formats of visual analog scales for use in standard rheumatology clinical care: Agreement between 10 cm horizontal line and 21 numbered circles. Arthritis Rheum. 2006;54(Suppl):S345.
35. Pincus T, Bergman M, Yazici Y, et al. Time to score various formats of a multidimensional health assessment questionnaire (MDHAQ): Which format would be best for standard clinical care? Arthritis Rheum 2006;54(Suppl):S703.
36. Kishimoto M, Tokuda Y, Yazici Y. RAPID, a simple easy to use patient reported outcome index, is strongly correlated with DAS28 and CDAI indices when monitoring rheumatoid arthritis patients in routine care. Arthritis Rheum. 2006;54(Suppl): S350.